Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Wildon R. Farwell
PharmaShots Interview: Biogen’s Wildon R. Farwell Shares Insight on Phase 4 RESPOND Study of Spinraza
In an interview with PharmaShots, Wildon R. Farwell, M.D., MPH, Global Medical Head of Neuromuscular Diseases at Biogen shared his views on the P-IV RESPOND study that assesses the benefits of Spinraza in patients treated with Zolgensma. Shots: RESPOND is a two-year, open-label study to evaluate the efficacy and safety of Spinraza (nusinersen) in infants and children with spinal muscular…
March 19, 2021
Viewpoints_Daniel A. de Boer
PharmaShots Interview: ProQR’s Daniel A. de Boer Shares Insight on Sepofarsen, the First Treatment for Leber Congenital Amaurosis 10 (LCA10)
In an interview with PharmaShots, Daniel A. de Boer of ProQR shared his views on P-II/III pivotal trial of Sepofarsen to treat the root cause of a rare eye disease, Leber congenital amaurosis 10 (LCA10) Shots: The Illuminate P-II/III trial of sepofarsen is a double-masked, randomized, controlled, multiple-dose study to evaluate if sepofarsen is effective at improving vision and is…
March 8, 2021
Viewpoints_Megan Bailey
PharmaShots Interview: PGDx’s Megan Bailey Shares Insight on the Partnership with QIAGEN and Almac
In an interview with PharmaShots, Megan Bailey, CEO of PGDx shared her views on PGDx's collaboration with QIAGEN and Almac to advance cancer diagnostics and make precision medicine more accessible to healthcare systems, laboratories, and patients globally. Shots: On Jan 11, 2021, PGDx and Almac collaborated to enhance patient care in the oncology On Jan 13, 2021, PGDx collaborated…
March 3, 2021
Viewpoints_Tillman Gerngross
PharmaShots Interview: Adagio Therapeutics’ Tillman Gerngross Shares Insight on the Development of Antibodies to Prevent COVID-19
In an interview with PharmaShots, Tillman Gerngross, Ph.D., Co-Founder, and CEO of Adagio Therapeutics shed light on the pre-clinical data of ADG2 and how it works on SARS-CoV-2. Shots: ADG2 showed broad and potent neutralizing activity against SARS-CoV and two SARS-related coronaviruses currently known to be circulating in bat populations (WIV-1 and SHC014) The company expects ADG20 to enter clinical studies…
March 1, 2021
Viewpoints_Ying Huang
PharmaShots Interview: Legend’s Ying Huang Shares Insight on ASH 2020 Data and Initiation of BLA Rolling Submission for Cilta-cel
In an interview with PharmaShots, Ying Huang, Ph.D., CEO and CFO of Legend Biotech shed light on the clinical data following the rolling submission of BLA for Cilta-cel. He also shared insight on Legends' collaboration with Janssen. Shots: The submission of BLA was based on results from the P-Ib/II CARTITUDE-1 study of cilta-cel, which were recently presented at the 62nd ASH Meeting The…
February 25, 2021
Viewpoints_Steve Bradford
PharmaShots Interview: GSK’s Steve Bradford Shares Insight on Benlysta
In an interview with PharmaShots, Steve Bradford, Vice President, Medicines Commercialization Leader at GSK shed light on the US FDA's approval of Benlysta as the first and only approved treatment for both lupus and adult patients with active LN who are receiving standard therapy. Shots: The US FDA has approved GSK's Benlysta (belimumab) as the first and…
February 24, 2021
Viewpoints_Dr. Sophia Randolph
PharmaShots Interview: ALX Oncology’s Dr. Sophia Randolph Shares Insight on the Clinical Collaboration with Zymework
In an interview with PharmaShot, Dr. Sophia Randolph, Chief Medical Officer of ALX Oncology shared her views on the ALX Oncology's collaboration with Zymework for evaluating the combination with ALX148 and zanidatamab for patients with advanced HER2-expressing breast cancer and other HER2-expressing solid tumors. Shots: Zymeworks will conduct a P-Ib study to assess the safety and efficacy of the combination…
February 22, 2021
Load more